Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Stock Holdings Lifted by Janus Henderson Group PLC

Janus Henderson Group PLC lifted its holdings in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) by 14.4% during the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 1,085,648 shares of the company’s stock after buying an additional 136,314 shares during the quarter. Janus Henderson Group PLC owned approximately 3.67% of Dianthus Therapeutics worth $23,607,000 as of its most recent filing with the SEC.

A number of other large investors also recently modified their holdings of DNTH. TCG Crossover Management LLC bought a new position in shares of Dianthus Therapeutics in the 4th quarter worth about $32,735,000. Braidwell LP increased its holdings in shares of Dianthus Therapeutics by 144.4% in the 4th quarter. Braidwell LP now owns 1,206,589 shares of the company’s stock worth $26,304,000 after acquiring an additional 712,902 shares during the period. Adage Capital Partners GP L.L.C. acquired a new stake in shares of Dianthus Therapeutics in the 4th quarter worth about $3,924,000. Alliancebernstein L.P. increased its holdings in shares of Dianthus Therapeutics by 13.4% in the 4th quarter. Alliancebernstein L.P. now owns 1,159,776 shares of the company’s stock worth $25,283,000 after acquiring an additional 136,633 shares during the period. Finally, Ally Bridge Group NY LLC acquired a new stake in shares of Dianthus Therapeutics in the 4th quarter worth about $2,320,000. 47.53% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of analysts recently weighed in on DNTH shares. Robert W. Baird dropped their price objective on shares of Dianthus Therapeutics from $58.00 to $50.00 and set an “outperform” rating on the stock in a report on Tuesday. Wedbush reaffirmed an “outperform” rating and issued a $36.00 price objective on shares of Dianthus Therapeutics in a report on Wednesday, March 12th. HC Wainwright reaffirmed a “buy” rating and issued a $40.00 price objective on shares of Dianthus Therapeutics in a report on Tuesday. Finally, Guggenheim reaffirmed a “buy” rating and issued a $84.00 price objective on shares of Dianthus Therapeutics in a report on Wednesday, March 12th. Seven investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus target price of $53.00.

Dianthus Therapeutics Trading Down 0.8%

Dianthus Therapeutics stock opened at $18.75 on Friday. The stock has a market cap of $602.36 million, a price-to-earnings ratio of -7.50 and a beta of 1.48. The company’s 50-day moving average price is $19.47 and its two-hundred day moving average price is $22.21. Dianthus Therapeutics, Inc. has a 52 week low of $13.37 and a 52 week high of $32.27.

Dianthus Therapeutics (NASDAQ:DNTH) last posted its quarterly earnings data on Monday, May 12th. The company reported ($0.82) earnings per share for the quarter, beating the consensus estimate of ($0.86) by $0.04. Dianthus Therapeutics had a negative net margin of 1,250.32% and a negative return on equity of 21.68%. The company had revenue of $1.16 million during the quarter, compared to analyst estimates of $0.81 million. Research analysts expect that Dianthus Therapeutics, Inc. will post -2.61 earnings per share for the current fiscal year.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.